CD4 and neoplasm: These results suggest that immunotherapies that can exert potent anti-tumor activity, such as anti-PD-1/4-1BB or anti-CD4 mAb in this study, successfully re-activate and expand putatively pre-existing tumor-reactive T-cells in the animal.